Otonomy, Inc. Logo
Otonomy Appoints Eric Loumeau as General Counsel and Chief Compliance Officer
May 18, 2015 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Appoints Dean Hakanson, M.D., as Chief Medical Officer
April 01, 2015 07:00 ET | Otonomy, Inc.
SAN DIEGO, April 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Present at the J.P. Morgan Healthcare Conference
January 06, 2015 08:00 ET | Otonomy, Inc.
SAN DIEGO, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere's Disease
December 01, 2014 07:00 ET | Otonomy, Inc.
SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Present at the Piper Jaffray Healthcare Conference
November 20, 2014 08:30 ET | Otonomy, Inc.
SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Reports Third Quarter 2014 Financial Results and Provides Corporate Update
November 12, 2014 16:05 ET | Otonomy, Inc.
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus
November 06, 2014 01:00 ET | Otonomy, Inc.
SAN DIEGO and PARIS, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
Otonomy, Inc. Logo
Otonomy Appoints Anthony J. Yost Chief Commercial Officer
October 21, 2014 07:29 ET | Otonomy, Inc.
SAN DIEGO, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Enrolls First Meniere's Disease Patients in OTO-104 Multiple-Dose Safety Study
October 09, 2014 07:30 ET | Otonomy, Inc.
SAN DIEGO, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Added To Russell 2000(R) Index
October 01, 2014 08:00 ET | Otonomy, Inc.
SAN DIEGO, Oct. 1, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...